The meeting of the Board of Directors of the Company was held on November 14, 2025, which inter alia considered and took on record the unaudited standalone and consolidated financial results ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
GKB Ophthalmics reported its Q2 and H1 FY26 results (ended Sep 30, 2025). On a standalone basis, revenue fell sharply — Q2 revenue dropped to Rs. 610.64 lakhs (vs Rs. 825.74 lakhs a year ago, ~26% decline) and H1 revenue fell to Rs. 1,488.13 lakhs (vs Rs. 1,687.64 lakhs). Standalone losses narrowed to Rs. 52.26 lakhs in Q2 and Rs. 266.56 lakhs in H1. On a consolidated basis, the picture improved significantly — H1 revenue grew ~20% to Rs. 6,247.73 lakhs and PAT swung to a profit of Rs. 120.05 lakhs from a loss of Rs. 104.51 lakhs last year. The Board approved closure of its tiny South African step-down subsidiary (Prime Ophthalmic Products PTY) due to inability to sustain operations, and noted a Rs. 8.82 crore labour recovery order is being challenged in the Bombay High Court at Goa. A Rs. 5 crore unsecured loan at 9.25% from Managing Director K.G. Gupta was approved to repay a loan from GSV Ophthalmics, which is being voluntarily wound up.
Consolidated results show a clear turnaround into profitability with strong revenue growth, but standalone operations remain deep in the red, signalling stress in the core Indian business. The MD personally funding the company and closure of subsidiaries point to ongoing financial pressure; shareholders should weigh improving group-level numbers against persistent standalone losses and the contingent labour order.